Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: iSpecimen operates a technology-driven marketplace connecting life science researchers with healthcare providers to procure human biospecimens (biofluids, tissues, cells) and associated data. The company acts as a principal in transactions, procuring specimens from a global network of supply partners and distributing them to biopharmaceutical, diagnostic, and government/academic customers.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $9,291,115 | $9,928,184 |
| Cost of Revenue | $5,302,712 | $4,820,268 |
| Gross Profit | $3,988,403 | $5,107,916 |
| Gross Margin | 42.9% | 51.4% |
| Net Loss | $(12,497,805) | $(11,099,488) |
| Operating Cash Flow | $(8,263,713) | $(5,807,550) |
| Cash and Equivalents (End of Period) | $1,878,408 | $2,343,666 |
| Working Capital | $(2,182,488) | $2,189,673 |
| Accumulated Deficit | $(71,862,617) | $(59,364,812) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 6% year-over-year to $9.3 million. This was driven by a write-off of unbilled revenue and a slight decrease in specimen volume (24,397 vs. 24,565), partially offset by a 1% increase in average selling price per specimen.
- Margin Compression: Gross margin declined from 51.4% to 42.9%. While specimen volume was relatively flat, the average cost per specimen increased 11% (from $196 to $217), driven by supply chain dynamics and a shift in product mix.
- Expense Management: Total operating expenses increased 4% to $22.0 million. Notable changes include a 25% increase in Sales and Marketing expenses (due to external marketing spend) and a 48% decrease in Supply Development expenses (due to reduced professional fees and payroll).
- Liquidity Shift: The company moved from a positive working capital position in 2023 to a deficit of $2.2 million in 2024. Cash reserves decreased by $465,000, and the company liquidated all available-for-sale securities ($2.66 million in 2023 to $0 in 2024).
- Capital Structure: The company executed a 1-for-20 reverse stock split in September 2024 to regain Nasdaq compliance. It also raised approximately $6.5 million in gross proceeds through an At-The-Market offering and a public equity offering (pre-funded warrants) in late 2024.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
The auditors have issued a "Going Concern" opinion. The company has incurred recurring losses, has a significant accumulated deficit, and a working capital deficit. Management's plan to mitigate this includes cost reductions, revenue enhancement projects, and raising additional capital. However, there is no assurance these plans will be successful.
Material Weakness in Internal Controls
The company identified a material weakness in internal control over financial reporting related to the failure to maintain documentation for customer tax-exempt status and the timely calculation, collection, and remittance of sales taxes. Remediation efforts are ongoing, including the implementation of sales tax software and engagement of external tax advisors.
Legal Proceedings and Contingencies
- Focus Technologies Litigation: A vendor filed a complaint for non-payment of IT services (~$489k). This led to a temporary shutdown of the iSpecimen Marketplace in January/February 2025. A settlement was reached for $500k, but the vendor failed to fully restore services, leading to a breach notice and counterclaims. The court has ordered the company to deposit 15% of revenue into a dedicated account up to $420,000 as pre-judgment security.
- Sales Tax Liability: The company accrued a sales tax liability of approximately $405,000 plus penalties as of December 31, 2024, related to prior years where taxes were not collected. The company is actively recovering these amounts from customers.
Outlook and Strategy
Management is focusing on "right-sizing" the company, having reduced workforce and technology costs significantly compared to 2023. Strategic priorities include shifting from high-volume to high-value suppliers, implementing a "next-day quote" system to improve conversion rates, and reorganizing the commercial sales team. The company anticipates continuing to incur losses for the foreseeable future.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.88 million cash balance against the current burn rate and the timeline for securing additional financing.
- Legal Exposure: Monitor the status of the Focus Technologies litigation and the impact of the court-ordered revenue escrow on liquidity.
- Sales Tax Recovery: Assess the progress of recovering the ~$405k sales tax liability from customers and the potential for additional unrecognized liabilities.
- Customer Concentration: Note that one customer accounted for approximately 29% of 2024 revenue; verify the stability of this relationship.
- Internal Controls: Review future filings for confirmation that the material weakness regarding sales tax and financial reporting has been remediated.